News | October 24, 2007

Medtronic’s DES Outperforms its BMS

October 24, 2007 - Presented at the TCT 2007 meeting, a pooled analysis of safety data from Medtronic’s ENDEAVOR clinical program affirmed the superior safety of the Endeavor drug-eluting coronary stent compared to Medtronic’s bare metal stent, Driver, indicating comparable safety to a bare-metal stent.

The analysis illustrated that Endeavor (n=2,132), when compared to Driver (n=596), was associated with low rates of all evaluated safety metrics. For Endeavor the respective rates, cumulatively, at three years were: heart attack (2.7%), stent thrombosis (0.7%), death (3.2%) cardiac death (1.0%). For Driver, the rates were: heart attack (4.2%), stent thrombosis (1.5%), death, (4.5%), cardiac death (2.4%).

These results mirror those of ENDEAVOR II, a 1,200-patient randomized clinical trial which directly compared Endeavor to Driver. In ENDEAVOR II, the Endeavor stent was associated with lower absolute rates of cardiac death, heart attack and stent thrombosis in follow up to three years.

The results were not only indicative of comparable safety to a bare-metal stent, they were also consistent in more challenging patient groups. For patients with diabetes or complex lesions, for whom safety is an even greater concern, Endeavor was found to have performed at least as well as the bare-metal stent across all measured safety metrics.

Laura Mauri, M.D., MSc, chief scientific officer of the Harvard Clinical Research Institute, and interventional cardiologist at the Brigham and Women’s Hospital, the author of the analysis, said, “Many of today’s cardiologists are concerned about the safety of drug-eluting stents compared to their bare-metal precursors, which are considered a benchmark for long-term safety. We were encouraged to have concluded that the next-generation Endeavor drug-eluting stent was associated with numerically fewer adverse events than the Driver bare-metal stent, itself a stent noted for its performance and safety characteristics.”

For more information: www.medtronic.com

Related Content

Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
Overlay Init